Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02646371 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a
A Phase 2 study of Shigellosis, sponsored by LimmaTech Biologics.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 1
- Study location
NCT02646371 is a Phase 2 study of Shigellosis that has completed, run by LimmaTech Biologics. The registered enrollment target is 67 participants, roughly in line with the 67-participant average among 3 other Shigellosis trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT02646371, a Phase 2 study of Shigellosis, has completed, sponsored by LimmaTech Biologics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 1
- Study location
Study Summary
In this proof of concept challenge study, the bioconjugate candidate vaccine Flexyn2a will be tested for its ability to induce an immune response that protects healthy adult volunteers from infection with a wild-type Shigella flexneri 2a strain compared to subjects receiving placebo.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Flexyn2a
Study Locations (1)
Maryland
- Johns Hopkins Bloomberg School of Public Health, CIR - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02646371
The ClinicalTrials.gov registry entry for NCT02646371 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 67-participant average among 3 other Shigellosis trials with a reported enrollment target. The listed sponsor is LimmaTech Biologics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Shigellosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02646371 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02646371 about?
NCT02646371 is a clinical study titled "Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a". In this proof of concept challenge study, the bioconjugate candidate vaccine Flexyn2a will be tested for its ability to induce an immune response that protects healthy adult volunteers from infection with a wild-type Shigella flexneri 2a strain compared to subjects receiving placebo.
What is the current status of trial NCT02646371?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2015-12. Estimated completion is 2017-07.
What conditions does trial NCT02646371 study?
This clinical trial studies the following conditions: Shigellosis.
What interventions are being tested in trial NCT02646371?
The interventions under investigation include: Placebo (BIOLOGICAL), Flexyn2a (BIOLOGICAL).
Who is sponsoring clinical trial NCT02646371?
This trial is sponsored by LimmaTech Biologics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02646371 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Shigellosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine
RECRUITING · Phase 2
-
Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.